TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12867217
Drug: Aprepitant 125
Normalized name: aprepitant 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 125 mg PO with granisetron 2 mg PO on day 1, followed by aprepitant 80 mg PO on days 2 and 3
Study: 12867217
Drug: Dexamethasone 20
Normalized name: dexamethasone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 20 mg PO and ondansetron 32 mg IV on day 1, followed by dexamethasone 8 mg PO on days 2 through 5
Study: 12867217
Drug: Granisetron 2
Normalized name: granisetron 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 2 mg PO on day 1 only
Study: 9194649
Drug: 2, 4
Normalized name: Kera-42, 42% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2, 4 or 8 mg of micronized MENT (single i.m. injections)
Study: 9194649
Drug: 1, 2
Normalized name: 1, 2-benzenediol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1, 2 or 4 mg of MENT (six consecutive daily i.m. injections)
Study: 1587077
Drug: Targeted intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted intermittent medication
Study: 1587077
Drug: Upward dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upward dose adjustment
Study: 11694805
Drug: Oral zafirlukast
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral zafirlukast (40 mg)
Study: 11694805
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of inhaled salmeterol and oral zafirlukast
Study: 8194818
Drug: DMSO gel
Normalized name: DMSO
DrugBank: Dimethyl sulfoxide (DB01093)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DMSO gel 10% applied three times a day (n = 77)
Study: 8194818
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel excipient (n = 80)
Study: 31858950
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control condition of daily maths activities
Study: 27400966
Drug: Nondirective coaching
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondirective coaching for subgroups (income above median, recent quit attempts, alternative therapies)
Study: 24522623
Drug: Lottery incentive
Normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [BEACH DREAM GLITTERY SUNSCREEN SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lottery incentive with expected daily value of $1.40 (n=21)
Study: 24522623
Drug: Lottery incentive
Normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [BEACH DREAM GLITTERY SUNSCREEN SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lottery incentive with expected daily value of $2.80 (n=26)
Study: 20068289
Drug: Vinegar (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinegar (10 g) during mealtime
Study: 20068289
Drug: Vinegar (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinegar (10 g) 5 hours before meal
Study: 19008149
Drug: BNP guided
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP guided therapy
Study: 16079784
Drug: Estimates of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estimates of k(loss) and EDV(2) using a novel application of a multilinear solution for the two-tissue compartment FDOPA model.
Study: 10423659
Drug: Lisinopril (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (n = 193)
Study: 6844367
Drug: Phentermine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine (30 mg capsule daily)
Study: 6844367
Drug: Diethylpropion (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylpropion (75 mg tablet daily)
Study: 25895909
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with standardized JC pollen extract (CEDARTOLEN®) at a maintenance dose of 2,000 Japanese allergy units (JAU)
Study: 25895909
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with standardized JC pollen extract (CEDARTOLEN®)
Study: 23900032
Drug: Nonlinguistic cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonlinguistic cognitive processing treatment
Study: 23900032
Drug: English treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: English treatment
Study: 23900032
Drug: Bilingual (Spanish-English)
Normalized name: Nitroglycerin Lingual Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilingual (Spanish-English) treatment
Study: 12612143
Drug: SPE chips
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPE chips and spread group (17 g/d SPE)
Study: 12612143
Drug: SPE spread
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPE spread (10 g/d SPE)
Study: 12612143
Drug: SPE chips
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPE chips (7 g/d SPE)
Study: 10690834
Drug: Near confluent
Normalized name: Albatrellus confluens fruiting body extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Near confluent laser treatment
Study: 10690834
Drug: Less dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less dense treatment
Study: 3720569
Drug: Special intervention
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special intervention (diuretic use)
Study: 30340813
Drug: Cranberry functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry functional beverage (CFB), 750 ml daily for 8 weeks
Study: 22453675
Drug: Lichtenstein repair
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lichtenstein repair with lightweight polypropylene mesh (L group)
Study: 20400496
Drug: Meals with
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meals with 250 to 3000 kcal containing 500 mg of calcium
Study: 8674787
Drug: Roxithromycin (ROM)
Normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (ROM) administered for 8 weeks
Study: 1839759
Drug: Teicoplanin 15
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 15 mg/kg
Study: 1839759
Drug: Teicoplanin 20
Normalized name: Teicoplanin 200 mg powder for solution for injection vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 20 mg/kg
Study: 1839759
Drug: Teicoplanin 25
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 25 mg/kg
Study: 6636790
Drug: Inderal 40
Normalized name: Inderal 40mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inderal 40 mg
Study: 6636790
Drug: Inderal 40
Normalized name: Inderal 40mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inderal 40 mg (in soldiers with anxiety and high pulse)
Study: 31447129
Drug: Intravenous fixed-dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fixed-dose combination (FDC) of ibuprofen 300 mg + acetaminophen 1000 mg
Study: 30126463
Drug: Mobile fresh
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile fresh fruit and vegetable (F&V) markets plus nutrition education (e.g. campaigns, DVDs, newsletters, recipes, and chef demonstrations)
Study: 26575696
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with Dermatophagoides farinae (Der.f) drops
Study: 26575696
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with Dermatophagoides farinae (Der.f) drops (SLIT3 subgroup)
Study: 26575696
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with Dermatophagoides farinae (Der.f) drops (SLIT1 and SLIT2 subgroups)
Study: 26575696
Drug: Pharmacotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy with oral antihistamines
Study: 25155941
Drug: Acceptance‐Enhanced Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance‐Enhanced Behavior Therapy for Trichotillomania
Study: 20963638
Drug: Chemotherapy (ifosfamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (ifosfamide, DTIC, and doxorubicin administered in 14-day intervals supported by G-CSF on days 5-13)
Study: 20963638
Drug: Chemotherapy (ifosfamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (ifosfamide, DTIC, and doxorubicin)
Study: 17351950
Drug: Oral gefitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gefitinib 250 mg daily (G arm)
Study: 17351950
Drug: Vinorelbine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 15 mg/m2 as an intravenous infusion on Day 1 and oral gefitinib 250 mg daily on Days 2 through 14 every 2 weeks (GV arm)
Study: 16278618
Drug: E(2) 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2) 0.25 mg
Study: 16278618
Drug: E(2) 1
Normalized name: vitamin E 1 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2) 1 mg
Study: 16278618
Drug: E(2) 2
Normalized name: (E)-2-butenedioic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2) 2 mg/NETA 1 mg
Study: 16278618
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (all E(2) groups)
Study: 11932567
Drug: Acustat electro‐membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acustat electro‐membrane microcurrent therapy
Study: 7620745
Drug: Morning light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning light treatment (8.00-8.30 a.m., n = 14)
Study: 7620745
Drug: Afternoon light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afternoon light treatment (1.00-1.30 p.m., n = 15)
Study: 7620745
Drug: Evening light
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening light treatment (8.00-8.30 p.m., n = 12)
Study: 7620745
Drug: Morning light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning light treatment followed by evening light (n = 13)
Study: 7620745
Drug: Evening light
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening light treatment followed by morning light (n = 14)
Study: 2371420
Drug: Healthy subjects
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy subjects using the roadside alcolmeter at flow rates of 10 l min‐1 and 40 l min‐1
Study: 7318359
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg by mouth)
Study: 29219095
Drug: Compliance with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliance with any combination of two guidelines
Study: 25595104
Drug: Alkalinized solution
Normalized name: ALKALINE AROMATIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkalinized solution (lidocaine 1% and epinephrine in sodium bicarbonate 1.4%)
Study: 25595104
Drug: Standard solution
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard solution (lidocaine 1% and epinephrine in saline 0.9%)
Study: 22748702
Drug: Apremilast 10
Normalized name: apremilast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 10 mg twice daily
Study: 17504124
Drug: Molecular targeted
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular targeted drugs (e.g., Glivec/Imatinib)
Study: 17504124
Drug: Chemotherapy drugs
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy drugs
Study: 17699247
Drug: Prednisone 60
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 60 mg/m2 every other day for 3 months, then 40 mg/m2 every other day for 9 months, then 30 mg/m2 every other day for 12 months
Study: 17699247
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids 4 g/d for 2 years (1.88 g eicosapentaenoic acid, 1.48 g docosahexaenoic acid)
Study: 10100270
Drug: Ondansetron (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (5 mg/m2 30 min before chemotherapy, then 4 mg/m2 every 8 h i.v.)
Study: 10100270
Drug: Tropisetron (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (0.2 mg/kg 30 min before chemotherapy, max dose 5 mg)
Study: 8092559
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate 200 micrograms once daily
Study: 1853146
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole once daily (maintenance treatment)
Study: 1853146
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine twice daily (maintenance treatment)
Study: 29428426
Drug: Bismuth-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy (Pylera)
Study: 29428426
Drug: 14-days sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-days sequential therapy
Study: 26949703
Drug: BNP (0.005 μg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP (0.005 μg/kg/min before contrast media exposure and saline hydration)
Study: 23018437
Drug: AS03A‐adjuvanted H1N1v
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03A‐adjuvanted H1N1v vaccine (3.75 μg haemagglutinin)
Study: 23018437
Drug: Nonadjuvanted H1N1v
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted H1N1v vaccine (15 μg haemagglutinin)
Study: 23018437
Drug: AS03A‐adjuvanted H1N1v
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03A‐adjuvanted H1N1v vaccine
Study: 12911461
Drug: NMDA-antagonist memantine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMDA-antagonist memantine
Study: 6731261
Drug: Propranolol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.2 mg/kg)
Study: 12754030
Drug: Topical vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical vancomycin (500mg)
Study: 11003358
Drug: Basiliximab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (20 mg on day 0 and day 4 posttransplantation)
Study: 1448311
Drug: Oral rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rifampin (20 mg/kg/day for 4 days)
Study: 21357819
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy with a defibrillator (CRT-D) in patients with LBBB
Study: 21357819
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy with a defibrillator (CRT-D) in patients with non-LBBB
Study: 19663668
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid therapy
Study: 11772140
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (25, 50, 75, and 100 microg/h, replaced every 3 days)
Study: 10223542
Drug: IFN‐alpha2b (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha2b (3 MU three times weekly, intramuscularly)
Study: 2204343
Drug: Enciprazine (D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enciprazine (D 13 112), dosage not specified
Study: 2204343
Drug: Enciprazine (D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enciprazine (D 13 112), highest dosage
Study: 28301282
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg hepatitis B vaccine (IM20 group)
Study: 28301282
Drug: 60 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 µg hepatitis B vaccine (IM60 group)
Study: 21492926
Drug: 360 days
Normalized name: LUVISET 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 days of antiretroviral therapy
Study: 21492926
Drug: Tuberculin skin
Normalized name: tuberculin skin test; unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberculin skin test positive participants receiving continued isoniazid treatment
Study: 21492926
Drug: Tuberculin skin
Normalized name: tuberculin skin test; unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberculin skin test negative participants receiving continued isoniazid treatment
Study: 16717465
Drug: Early tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early tirofiban administration (n = 32)
Study: 16717465
Drug: Late tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late tirofiban administration (n = 34)
Study: 10795728
Drug: Yohimbine (0.65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (0.65 mg/kg)
Study: 2061566
Drug: Benfluorex (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfluorex (450 mg/day)
Study: 6635447
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg once daily for three days
Study: 6635447
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg plus trimethoprim 160 mg once daily for three days
Study: 6635447
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of rifampin 600 mg plus trimethoprim 160 mg
Study: 3842545
Drug: 2 G
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 G of salt in the morning and a placebo in the evening
Study: 3842545
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in the morning and 2 G of salt in the evening
Study: 22437792
Drug: Oral recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral recombinant salmon calcitonin (rsCT) tablets (0.2 mg/d) plus placebo nasal spray
Study: 22437792
Drug: Synthetic salmon
Normalized name: Synthetic salmon calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic salmon calcitonin (ssCT) nasal spray (200 IU/d) plus placebo tablets
Study: 22437792
Drug: Placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo tablets plus placebo nasal spray)
Study: 22437792
Drug: Oral recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral recombinant salmon calcitonin (rsCT) tablets
Study: 18333888
Drug: PHX1149 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHX1149 100 mg
Study: 18333888
Drug: PHX1149 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHX1149 200 mg
Study: 18333888
Drug: PHX1149 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHX1149 400 mg
Study: 10371259
Drug: Alcohol day
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol day (0.35 g/kg of 95% alcohol)
Study: 10371259
Drug: Placebo day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo day (1 ml of alcohol in 240 ml beverages)
Study: 8877028
Drug: gamma‐L‐glutamyl‐5‐hydroxy‐L‐tryptophan (glu‐5‐HTP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gamma‐L‐glutamyl‐5‐hydroxy‐L‐tryptophan (glu‐5‐HTP)
Study: 8877028
Drug: gamma‐L‐glutamyl-L‐tryptophan (glu‐TRP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gamma‐L‐glutamyl-L‐tryptophan (glu‐TRP)
Study: 1673736
Drug: Continued antiepileptic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued antiepileptic treatment
Study: 1673736
Drug: Slow withdrawal
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow withdrawal of antiepileptic treatment
Study: 6873851
Drug: Both new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both new suppository preparations
Study: 29503371
Drug: Facial exercises
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Facial exercises program (30 min, twice a week for 12 weeks)
Study: 27177079
Drug: Group schema
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group schema therapy (ST)
Study: 22377796
Drug: Black currant
Normalized name: Black currant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black currant anthocyanins (BCACs) 50 mg/day (n = 19)
Study: 19700304
Drug: Sustained-release oral
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release oral oxycodone 20mg followed by immediate-release oxycodone 10mg 6-hourly for the first 24h (group O)
Study: 19700304
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 100mug (group I)
Study: 18355324
Drug: Saxagliptin (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin (low-dose cohort: 2.5, 5, 10, 20 or 40 mg once daily for 12 weeks)
Study: 18355324
Drug: Saxagliptin (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin (high-dose cohort: 100 mg once daily for 6 weeks)
Study: 1800760
Drug: Labetalol 100
Normalized name: HCTZ 25/LABETALOL 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 100 mg twice daily (n = 30)
Study: 1800760
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 25 mg twice daily (n = 31)
Study: 12529075
Drug: Caffeine (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (4.0 mg/kg)
Study: 20420475
Drug: Step‐down model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step‐down model (CP) consisting of initial short‐term day hospital treatment followed by conjoint group and individual outpatient treatment
Study: 16062017
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg orally) followed by misoprostol (800 micro gm intravaginally)
Study: 16062017
Drug: Methotrexate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (50 mg/m2 intramuscularly) followed by misoprostol (800 micro gm intravaginally)
Study: 10202166
Drug: Cisplatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (40 mg/m² once a week for up to six doses during radiotherapy)
Study: 7599666
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral bromocriptine (2.5-10.0 mg/day) during two consecutive 30-day periods (T-1 and T-2)
Study: 7599666
Drug: Intermittent oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent oral bromocriptine (from day 1 to 15 of each 30-day period)